![]() |
|
|
Vol. 283, Issue 3, 1130-1137, 1997
Department of Pulmonary Pharmacology, UW2532, SmithKline Beecham
Pharmaceuticals, King of Prussia, Pennsylvania
This study investigated the effects of the nonpeptide endothelin (ET)
receptor antagonist, SB 217242, against ET-1-induced pulmonary pressor
responses and in a model of hypoxia-induced pulmonary hypertension in
the guinea pig. In guinea pig isolated pulmonary artery rings, SB
217242 (3-300 nM) produced a concentration-dependent inhibition of
ET-1-induced contractions, with a pA2 of 8.1. SB 217242 (1 or 3 mg/kg i.v.) elicited a dose-related inhibition of ET-1-induced
increases in pulmonary artery and airway insufflation pressure
responses in anesthetized guinea pigs. Chronic exposure to hypoxia (9%
O2 for 0-14 days) produced a time-dependent increase in
mean pulmonary artery pressure. After a 10-day exposure to hypoxia
there was about a 100% elevation in pulmonary artery pressure, and
right ventricular mass and plasma irET levels increased 3-fold compared
with normoxic animals. SB 217242, administered by continuous intraperitoneal infusion via mini osmotic pump (0.36, 3.6 or 10.8 mg/day), significantly reduced (by about 50%)
hypoxia-induced pulmonary artery pressure increases at all three doses
used. The hypoxia-induced right ventricular hypertrophy was
significantly attenuated by the 3.6 and 10.8 mg/day doses. Based on
hematocrit, hemoglobin and red blood cell counts, SB 217242 did not
affect the normal physiological erythropoietic response to hypoxia.
There were no appreciable differences in the maximum contractile
effects of ET-1 or the potency of SB 217242 (pKB values,
8.3 and 8.0, respectively) versus ET-1-induced responses
in isolated pulmonary arteries from hypoxic versus
normoxic guinea pigs. However, there was a marked reduction in
endothelium-dependent relaxation of precontracted pulmonary artery
isolated from hypoxic compared with normoxic animals. The results of
the present study provide further preclinical evidence for a
pathophysiological role of ET-1 and the potential therapeutic utility
of ET receptor antagonists, such as SB 217242, in pulmonary
hypertension.
This article has been cited by other articles:
![]() |
V. Hampl, J. Bibova, A. Banasova, J. Uhlik, D. Mikova, O. Hnilickova, V. Lachmanova, and J. Herget Pulmonary vascular iNOS induction participates in the onset of chronic hypoxic pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, January 1, 2006; 290(1): L11 - L20. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. I. Aguirre, N. W. Morrell, L. Long, P. Clift, P. D. Upton, J. M. Polak, and M. R. Wilkins Vascular remodeling and ET-1 expression in rat strains with different responses to chronic hypoxia Am J Physiol Lung Cell Mol Physiol, May 1, 2000; 278(5): L981 - L987. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hanasato, M. Oka, M. Muramatsu, M. Nishino, H. Adachi, and Y. Fukuchi E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats Am J Physiol Lung Cell Mol Physiol, August 1, 1999; 277(2): L225 - L232. [Abstract] [Full Text] [PDF] |
||||